Jaren Madden
Investor Relations Contact bei SCHRÖDINGER, INC.
Profil
Jaren Irene Madden's current job is as the SVP-Investor Relations & Corporate Communications at Schrödinger, Inc. Ms. Madden's former jobs include being the Senior Director-Investor Relations at Infinity Pharmaceuticals, Inc. from 2013 to 2017, the VP-Investor Relations & Corporate Communications at Gamida Cell Ltd., and the Global Head-Research & Development Communications at Shire Plc from 2017 to 2018.
Ms. Madden's education includes an MBA from Boston University and undergraduate and graduate degrees from the University of Connecticut.
Aktive Positionen von Jaren Madden
| Unternehmen | Position | Beginn |
|---|---|---|
| SCHRÖDINGER, INC. | Investor Relations Contact | 01.11.2020 |
Ehemalige bekannte Positionen von Jaren Madden
| Unternehmen | Position | Ende |
|---|---|---|
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Chief Tech/Sci/R&D Officer | 01.07.2018 |
| INFINITY PHARMACEUTICALS, INC. | Investor Relations Contact | 01.01.2017 |
| GAMIDA CELL LTD. | Investor Relations Contact | - |
Ausbildung von Jaren Madden
| Boston University | Masters Business Admin |
| University of Connecticut | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| SCHRÖDINGER, INC. | Technology Services |
| GAMIDA CELL LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
